PDGFRA and gastrointestinal stromal tumor: Although the introduction of IM has helped transform patient outcomes in GIST, resistance develops in the majority of patients within 2 years of treatment, largely through the acquisition of secondary resistance mutations in KIT and PDGFRA ([63], [64], [65], [66], [67], [68]).